

AMENDMENT

It is respectfully requested that the application be amended without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents, as follows. A marked-up version of the amended claims entitled "VERSION WITH MARKINGS TO SHOW CHANGES MADE" is appended.

IN THE CLAIMS

Please add the following claims without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents.

42. (New) A method of reducing T-cell activation by administering a Notch ligand comprising a DSL domain to a patient in need thereof.

43. (New) The method of claim 42, wherein the *Notch* ligand is selected from the group consisting of the Serrate family of proteins and the Delta family of proteins.

44. (New) The method of claim 42, wherein the T-cell activation occurs with one or more conditions selected from the group consisting of allergy, autoimmunity, graft rejection and infectious disease.

45. (New) The method of claim 42, wherein the *Notch* ligand is Serrate.

46. (New) The method of claim 42, wherein the *Notch* ligand is Delta.

47. (New) The method of claim 42, wherein the T-cell activation occurs with one or more conditions selected from the group consisting of allergy, autoimmunity and graft rejection.

Please cancel claims 27-29 and 33-39 without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents.